no recurrence of chilblains after 18 months of treatment (Figure 1A) . Lesions also did not reappear during winter, when the disease was usually more active. No occurrences of viral infections, opportunistic infections, or other complications were reported during treatment.
Peripheral blood samples were collected from the patient 4 weeks prior to the start of baricitinib therapy and after 2 and 6 weeks of treatment. Expression levels of 5 ISGs (IFI44, IFI44L, IFIT3, LY6E, and MX1) representing the gene signature for type I IFN activity (9) were measured in isolated CD14+ monocytes by quantitative reverse transcription-polymerase chain reaction and compared to the expression levels in 54 healthy controls. Prior to baricitinib therapy, monocytes from the patient displayed higher expression of all tested ISGs compared to healthy controls ( Figure 1B) . Expression of all 5 ISGs declined remarkably after initiation of baricitinib treatment ( Figure 1B) .
Furthermore, we measured total STAT1 and phosphorylated STAT1 in peripheral blood T lymphocytes by flow cytometry (7) . Before and during treatment, T lymphocytes from the patient expressed higher levels of total STAT1 than those observed in 2 age-, sex-, and race-matched healthy controls ( Figure 1C ). As shown in Figures 1D and E, T lymphocytes from the patient before and during baricitinib therapy displayed baseline levels of phosphorylated STAT1 comparable to those in the healthy controls. However, T lymphocytes obtained from the patient before treatment displayed much higher levels of phosphorylated STAT1 upon IFNα stimulation than healthy control T lymphocytes. The enhanced level of phosphorylated STAT1 observed in patient T lymphocytes before baricitinib treatment was strongly reduced during treatment.
In summary, our findings suggest that baricitinib is a novel drug for the treatment of chilblains in AGS patients with a SAMHD1 mutation and consequent up-regulation of type I IFN activity. The immunologic effects of JAK inhibitors depend on their selectivity and inhibitory capacity for the several JAK subtypes. Baricitinib displays a stronger inhibitory effect on cytokine-induced phosphorylated STAT1 than ruxolitinib, which had been previously reported as successful in the treatment of STING-associated type I interferonopathy (6, 10) . Therefore, more in-depth research is warranted to evaluate baricitinib in the treatment of type I interferonopathies. The patient, an 11-year-old boy, presented with left heel pain and mild fever. He had recently experienced diffuse arthralgias of the right knee, costochondral junctions, and both ankles. Laboratory findings were normal except for a slightly increased erythrocyte sedimentation rate. Magnetic resonance imaging (MRI) of the left heel was performed. On T1-weighted and fat-suppressed T2-weighted MRI sequences, bone marrow edema with indistinct margins was seen at the posterior margin of the calcaneus, above the growth plate, and below its posterior and superior cortex (A and B) (arrows). The shape of the apophysis was preserved. Enhancement was seen in the area of the bone marrow edema after gadolinium injection (C) (arrow), and the calcaneal bursa was also enhanced. This pattern of marrow changes differed from the thin high-signal-intensity strip normally seen along the growth plate at this age and from the normal variant of scattered patchy areas sometimes present in the posterior calcaneus (D and E) (arrows) (1). Sever's disease was ruled out as it mainly affects the secondary ossification center. Spondyloarthritis was diagnosed based on the calcaneal bone marrow edema and the involvement of the adjacent soft tissues below the Achilles tendon in a clinical context of diffuse arthralgias. This case illustrates calcaneal involvement in juvenile spondyloarthritis, which consisted of bone marrow edema and gadolinium enhancement involving the superior area of the posterior calcaneus above the secondary ossification center as well as the calcaneal bursa. Interestingly, in this patient, bone marrow changes predominated in the superior part of the posterior calcaneus at the level of the periosteal fibrocartilage located above the secondary ossification center and the Achilles enthesis (2). 
